Sodium-glucose cotransporter-2 inhibitors: updated evidence on their efficacy and safety in patients with type-2 diabetes

Simple item page
dc.contributor.authorGupta, Vipulen_US
dc.contributor.authorKhurana, Girishen_US
dc.date.accessioned2020-04-23T08:01:42Z
dc.date.available2020-04-23T08:01:42Z
dc.date.issued2020-04
dc.description.abstractManagement of type-2 diabetes mellitus (T2DM) is challenging. The scope of existing therapies toward T2DM has transformed remarkably. These large assortments of therapies have produced evidence-based data. Sodium-glucose cotransporter-2 inhibitor (SGLT-2i) is the most recent class of oral anti-hyperglycemic agents. They are approved by Food and Drug Administration for the treatment of diabetes mellitus. SGLT-2i has a unique mechanism of action and that lower glucose independent of insulin. They reduce renal tubular glucose reabsorption, thereby lowering blood glucose without stimulating the release of insulin. Additional advantages involve suitable effects on blood pressure and weight. According to guidelines of the American Association of Clinical Endocrinologists/ the American College of Endocrinology 2016, SGLT-2i (in the form of canagliflozin, dapagliflozin, and empagliflozin) is one of the acceptable alternatives to metformin as initial therapy towards T2DM. Canagliflozin, dapagliflozin, and empagliflozin reduce the cardiovascular risk in comparison to placebo as the part of standard care. This review article focuses on the clinical trials published over the past year and specifically the metabolic aspect of SGLT-2i and the adverse effects related to SGLT-2 inhibitors.en_US
dc.identifier.affiliationsGupta Ultrasound and Heart Care Center, Paschim Vihar, New Delhi, Indiaen_US
dc.identifier.affiliationsVidya Medicare Center, Bahadur Garh, Haryana, Indiaen_US
dc.identifier.citationGupta Vipul, Khurana Girish. Sodium-glucose cotransporter-2 inhibitors: updated evidence on their efficacy and safety in patients with type-2 diabetes. International Journal of Basic & Clinical Pharmacology. 2020 Apr; 9(4): 666-673en_US
dc.identifier.issn2319-2003
dc.identifier.issn2279-0780
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/200591
dc.languageenen_US
dc.publisherMedip Academyen_US
dc.relation.issuenumber4en_US
dc.relation.volume9en_US
dc.source.urihttps://dx.doi.org/10.18203/2319-2003.ijbcp20201102en_US
dc.subjectSGLT2en_US
dc.subjectType 2 diabetes mellitusen_US
dc.subjectOral glucose-lowering medicinesen_US
dc.titleSodium-glucose cotransporter-2 inhibitors: updated evidence on their efficacy and safety in patients with type-2 diabetesen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijbcp2020v9n4p666.pdf
Size:
223.39 KB
Format:
Adobe Portable Document Format
Download
Collections
International Journal of Basic & Clinical Pharmacology